Planned website maintenance is taking place from 11:00 pm AEDT on Friday 30 October to 6:00 am AEDT on Saturday 31 October 2026. Some pages may be temporarily unavailable. If issues continue outside this time, please contact us.
OSMIVIR; OSELTAMIVIR STR; OSELTAMIVIR STRIDES (Strides Pharma Science Pty Ltd)
Product name
OSMIVIR; OSELTAMIVIR STR; OSELTAMIVIR STRIDES
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
148 (255 working days)
Active ingredients
oseltamivir (as phosphate)
Registration type
New generic medicine
Indication
OSMIVIR; OSELTAMIVIR STR; OSELTAMIVIR STRIDES (capsule) is indicated for the treatment of infections due to influenza A and B viruses in adults and children including full-term neonates. Treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.
OSMIVIR; OSELTAMIVIR STR; OSELTAMIVIR STRIDES is indicated for the prevention of influenza in adults and children aged 1 year and older. Vaccination is the preferred method of routine prophylaxis against infection with influenza virus.